ESMO Magnitude of Clinical Benefit Scale: Awareness and Utilisation Survey

The ESMO-MCBS was launched in May 2015 and was the first version of a validated and reproducible tool to assess the magnitude of clinical benefit from new cancer therapies.

ESMO is applying the scale in the grading of all new medications or indications of approved anti-neoplastic treatments in solid tumours by the European Medicines Agency since 2016. These grades are currently being presented in relevant ESMO Clinical Practice Guidelines or as an 'eUpdate', where we can rapidly inform of any changes and updates incorporating the ESMO-MCBS grade.


The objective of this survey is to understand the awareness of the ESMO-MCBS and how it is being used in supporting the work and decision-making process of various stakeholders.


It is expected to take approximately 5 minutes to complete this short survey and we kindly request you complete the survey in all its parts to the best of your knowledge:

Take the survey now

Participation is entirely voluntary, no action will be taken for refusal to participate and all responses are anonymous.


30 July 2017


Should you have any questions on how to complete the survey or have any technical issues, please contact Nicola Latino at

We take this opportunity to thank you very much for your time and invaluable input!